AzTrials
AzTrials

PARKINSON DISEASE (Disorder)NCT02118480

Improving Functional Disability and Cognition in Parkinson Disease: Randomized Controlled Trial

A study testing cognitive remediation program: REHACOP and Occupational Therapy in people with PARKINSON DISEASE (Disorder), run by University of Deusto at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study design was a parallel-group randomized trial with equal randomization. Recruitment and enrollment were conducted between June 2012 and January 2013. At base-line, clinical, cognitive and functional data was collected. Read more about this study

Who is it for?
Ages 45 to 75 years
Conditions the study is for
PARKINSON DISEASE (Disorder)
What is being tested?
cognitive remediation program: REHACOP and Occupational Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
44 participants
Where
1 siteSpain
Study dates
Jun 2012to Jun 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • diagnosis of PD based on the United Kingdom PD Society Brain Bank (PDSBB) diagnostic criteria
  • age 45-75 years
  • either male or female
  • Hoehn and Yahr disease stage 1-3 as evaluated by the neurologist

Who cannot join

  • the presence of dementia as defined by the (DSM-IV-TR) Diagnostic and statistical manual of mental disorders IV Test Revised and the Movement Disorders Society specific clinical criteria for PD-dementia
  • the presence of other neurological illness or injury (Traumatic Brain Injury, Multiple Sclerosis)
  • unstable psychiatric disorders such as schizophrenia or major depression
  • the presence of visual hallucinations as assessed by the Neuropsychiatric Inventory Questionnaire (NPI-Q)

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • University of Deusto

    Bilbao, Biskai, 48007

Other trials in Spain

About this study

The study design was a parallel-group randomized trial with equal randomization. Recruitment and enrollment were conducted between June 2012 and January 2013. At base-line, clinical, cognitive and functional data was collected. Afterwards, the participants were randomly allocated to either the REHACOP group or the Control group. During 3 months the intervention with REHACOP program took place and at follow-up patients were again re-evaluated to evaluate the changes in clinical, cognitive and functional measures. Post-treatment assessment (finished by June 2013) was performed within the first week after completing the intervention.Optional enrollment in pre- post neuroimaging will also allow us to look at changes in the brain. Finally, longitudinal follow-up at 18 months with neuropsychological and neuroimaging assessements was also performed.

Objective: To examine the efficacy of an integrative cognitive training program (REHACOP) to improve cognition, clinical symptoms and functional disability of patients with Parkinson disease (PD).

Read the detailed description

Assessment protocol:

  • Cognitive Evaluation: The cognitive battery included assessments to evaluate processing speed, verbal learning and memory, visual learning and memory and executive functioning. All cognitive measures were converted into Z-scores based on the pooled PD group, and the sign of some measures was adjusted so that higher scores indicated better cognitive performance. All composite cognitive domains maintained satisfactory internal consistency. Processing Speed (Cronbach's α = 0.85) was quantified based on the Trail Making Test-A and Salthouse Letter Comparison Test. For verbal learning and memory (α = 0.88), learning and long-term recall performance on the Hopkins Verbal Learning Test (version 2 at baseline and 4 at post-treatment) were utilized. For visual learning and memory (α = 0.96), learning and long-term recall performance on the Brief Visual Memory Test (version 1 at baseline and 3 at post-treatment) were used (α = 0.96). Executive functioning (α = 0.78) was determined based on the Stroop test, using the word-color and interference scores.

Theory of mind (TOM). The strange stories test (Happé test) was administered to evaluate TOM. Four different stories (concerning double bluff, mistakes, persuasion and white lies) were administered at baseline and follow-up, and they were summed into a total TOM score with a possible range of 0 to 8. Higher scores indicate better TOM.

  • Premorbid intelligence quotient and cognitive reserve. The Accentuation Reading Test (TAP), the Spanish version of the National Adult Reading Test (NART), was administered to calculate an estimation of each patient´s premorbid intelligence. The scale ranged from 0 to 30. Cognitive reserve was estimated using the Cognitive Reserve questionnaire. This 15-item multiple-choice questionnaire includes questions about education/culture, working activity, leisure and hobbies, physical activities and social activities. Higher scores indicate a better cognitive reserve, and the scale ranged from 0 to 26.
  • Global cognitive status. The Mini-Mental State Examination (MMSE) was administered to obtain a general mental status score.
  • Medication use. Medications, dosages and dose frequencies were used to calculate the levodopa-equivalent daily dose (mg/day) (LEDD).
  • PD assessment. The Unified Parkinson's Disease Rating Scale and the Hoehn \& Yahr scale were used for the assessment of the course and stage of the disease.
  • Depressive symptoms. Geriatric Depression Scale (GDS-15) includes 15 items. Higher scores represent a higher degree of depression (range from 0 to 15).
  • Neuropsychiatric symptoms. The NPI-Q was administered to evaluate neuropsychiatric symptoms. The test includes 10 items (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, euphoria, apathy, disinhibition, irritability and aberrant motor behavior). These sub-scales were summed into a total score with a possible range of 0 to 120. Higher scores indicate more frequent and severe neuropsychiatric symptoms.
  • Apathy. The Lille apathy rating scale consists of 33 items, including 9 sub-scales (everyday productivity, interests, taking initiative, novelty seeking/motivation, emotional responses, concern, social life and self-awareness). These sub-scales were summed into a total apathy score with a possible range of -36 to 36. Lower scores indicate less apathy.
  • Functional disability. Functional disability was self administered using the World Health Organization Disability Assessment Schedule II (WHO-DAS II), short version (12 items).

Description of the intervention:

  • REHACOP is a structured program using paper-pencil tasks and it is based on the principles of restoration, compensation and optimization with a gradually increasing level of cognitive effort and demand. REHACOP trains different cognitive domains, such as attention, memory, processing speed, language, executive functioning and social cognition. Additionally, the program includes one unit related to functional outcome: activities of daily living. REHACOP includes up to 300 different tasks hierarchically organized into at least three levels of difficulty and subtypes of abilities. Several tasks are timed, so processing speed is trained throughout various modules. Once a basic cognitive strategy has been trained and well acquired, the therapist transitions the program to the next level. The program format allows for either individual or group sessions (between 5 and 8 patients per group), although for the purpose of this study, group sessions were chosen. In this study, two psychologists conducted the REHACOP group attending 60-minute-long sessions 3 days per week at Parkinson Disease Association Biskay (ASPARBI) (two groups) or the Hospital of Galdakao (one group). Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
  • Occupational Activities: The Control group consisted of occupational group activities conducted by a psychologist at ASPARBI. The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.

A subset of the sample will also complete a pre and post neuroimaging to evaluate changes in structural and functional brain activation.

Being tested
cognitive remediation program: REHACOP, Occupational Therapy
Keywords
Parkinson disease, cognitive rehabilitation, REHACOP
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • cognitive remediation program: REHACOPOther

    Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.

  • Occupational TherapyOther

    The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.

Study groups in NCT02118480
Study groupRoleWhat they receive
cognitive remediation program: REHACOPExperimentalCognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
Receives: Other: cognitive remediation program: REHACOP
Occupational TherapyActive comparatorThe activities included drawing, reading the daily news and constructing using different materials (such as paper or wood) during 3 months, 3 times per week.
Receives: Other: Occupational Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in processing speed after receiving cognitive rehabilitation treatment

    Measured: 3 months

  2. Change in verbal memory performance after receiving cognitive remediation treatment

    Measured: 3 months

  3. Change in visual memory after receiving cognitive remediation treatment

    Measured: 3 months

  4. Change in executive functioning after receiving cognitive remediation treatment

    Measured: 3 months

  5. Change in theory of mind after receiving cognitive remediation treatment

    Measured: 3 months

Secondary outcomes (3)
  1. Change in apathy after receiving cognitive remediation treatment

    Measured: 3 months

  2. Change in functional disability after receiving cognitive remediation treatment

    Measured: 3 months

  3. Change in depression after receiving cognitive remediation treatment

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Apr 2014 (estimated)
  2. Study startJun 2012
  3. Primary completionJun 2013
  4. Study completionJun 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
44 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02118480
Sponsor's protocol ID
NSMC-001-UD
Status last verified
Jan 2018
First submitted
15 Apr 2014
Last updated
24 Jan 2018
Results posted
No
Data monitoring committee
Yes

Publications

  • Pena J, Ibarretxe-Bilbao N, Garcia-Gorostiaga I, Gomez-Beldarrain MA, Diez-Cirarda M, Ojeda N. Improving functional disability and cognition in Parkinson disease: randomized controlled trial. Neurology. 2014 Dec 2;83(23):2167-74. doi: 10.1212/WNL.0000000000001043. Epub 2014 Oct 31.

    PubMed 25361785

Questions about this trial

What is this clinical trial studying?

A study testing cognitive remediation program: REHACOP and Occupational Therapy in people with PARKINSON DISEASE (Disorder), run by University of Deusto at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in processing speed after receiving cognitive rehabilitation treatment (time frame: 3 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02118480, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jan 2018; AzTrials last refreshed its copy on 2 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in